1st Quarter - Amendment

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

Firm
Client
Income
—
Expenses
$1,040,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 20, 2018 $970,000 Replaced
1st Quarter - Amendment (this page) Dec 5, 2018 $1,040,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Taxation Issues Related to Opioid Pharmaceuticals. User Fee Programs.

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Government Accountability Office (GAO); Office of Management & Budget (OMB); Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR)

Trade (domestic/foreign) TRD

General Trade Issues. Trans-Pacific Partnership (TPP). Transatlantic Trade and Investment Partnership (TTIP). Biologic Exclusivity. North American Free Trade Agreement.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
MICHAEL BRZICA —
CHRISTIAN OMAR CRUZ —
JEFFREY FRANCER —
DAVID R. GAUGH —
ERIK C KOMENDANT —
KRISTIN MURPHY —

Contacted: SENATE; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Government Accountability Office (GAO); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS)

Copyright/Patent/Trademark CPT

Inter Partes Review (IPR) process. Patent Settlements. S.1390: STRONGER Patents Act of 2017. S.2514: PACED Act.

Contacted: Food & Drug Administration (FDA); SENATE; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); Government Accountability Office (GAO); Health & Human Services, Dept of (HHS)

Bills named: S. 1390 (115th), S. 2514 (115th)

Medicare/Medicaid MMM

Medicare Part D Program and Generic Drugs. Medicare Reimbursement for Biosimilars. Medicaid Rebate Penalty. Medicare Part D Low Income Subsidy (LIS) Program. Medicare Part D Coverage Gap Discount Program.

Contacted: Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR); Government Accountability Office (GAO); Centers For Medicare and Medicaid Services (CMS)

Budget/Appropriations BUD

FDA Funding. H.R.1892: Bipartisan Budget Act of 2018. H.R.1625: Consolidated Appropriations Act, 2018.

Contacted: HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Office of Management & Budget (OMB); Government Accountability Office (GAO)

Bills named: H.R. 1892 (115th), H.R. 1625 (115th)

Pharmacy PHA

Implementation of Food and Drug Administration Safety and Innovation Act (FDASIA). Generic Drug User Fee Amendments (GDUFA). Biosimilar User Fee Act (BsUFA). Labeling of Generic Drugs. Drug Compounding. Biosimilars Naming. Pass Through Payments for Biosimilars. Prescription Drug Costs. Opioid abuse. H.R.2051: FAST Generics Act of 2017. S.124: Preserve Access to Affordable Generics Act. H.R.1245/S.469: Affordable and Safe Prescription Drug Importation Act. H.R.1892: Bipartisan Budget Act of 2018. Risk Evaluation and Mitigation Strategies (REMS). Biologic Exclusivity. Biologics Price Competition and Innovation Act (BPCIA). H.R.2562/S.1115: Making Pharmaceutical Markets More Competitive Act. S.771: Improving Access To Affordable Prescription Drugs Act. Pharmaceutical Exclusivity. H.R.2212/S.974: CREATES Act of 2017. H.R.2439/S.1131: Fair Accountability and Innovative Research Drug Pricing Act of 2017. S.297: Increasing Competition in Pharmaceuticals Act. H.R.749: Lower Drug Costs through Competition Act. H.R.2430/S.934: FDA Reauthorization Act of 2017. H.R.1223/S.1509: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017. Discussion Draft of H.R.__, FDA Accelerated Approval and Breakthrough Therapy Status. Discussion Draft of H.R.__, FDA and International Mail. Discussion Draft of H.R.__, Opioid Sparing. Discussion Draft of H.R.__, Packaging and Disposal. Discussion Draft of H.R.__, Long-term Efficiency. Discussion Draft of H.R.__, Misuse/Abuse.

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); SENATE; Government Accountability Office (GAO); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 2051 (115th), S. 297 (115th), S. 1509 (115th), H.R. 2212 (115th), S. 124 (115th), S. 1115 (115th), H.R. 1245 (115th), H.R. 2562 (115th), S. 469 (115th), H.R. 2430 (115th), S. 1131 (115th), H.R. 749 (115th), H.R. 1223 (115th), S. 934 (115th), H.R. 2439 (115th), H.R. 1892 (115th), S. 771 (115th), S. 974 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.